{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:55:45Z","timestamp":1789217745811,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-12-1-0155"],"award-info":[{"award-number":["W81XWH-12-1-0155"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11060-025-05020-1","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:50:58Z","timestamp":1748429458000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104"],"prefix":"10.1007","volume":"173","author":[{"given":"Vihang","family":"Nakhate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Muzikansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Rapalino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian L.","family":"Campian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Wade","family":"Clapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Dhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh K.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias A.","family":"Karajannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tonsgard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole J.","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Korf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Neurofibromatosis Clinical Trials Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"issue":"9","key":"5020_CR1","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","volume":"24","author":"SR Plotkin","year":"2022","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24(9):1967\u20131977","journal-title":"Genet Med"},{"issue":"10","key":"5020_CR2","first-page":"1742","volume":"26","author":"JZ Wang","year":"2024","unstructured":"Wang JZ, Landry AP, Raleigh DR, Sahm F, Walsh KM, Goldbrunner R et al (2024) Meningioma: international consortium on meningiomas consensus review on scientific advances and treatment paradigms for clinicians, researchers, and patients. Neurooncology 26(10):1742\u20131780","journal-title":"Neurooncology"},{"issue":"1","key":"5020_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3109\/02688697.2014.952266","volume":"29","author":"R Aboukais","year":"2015","unstructured":"Aboukais R, Zairi F, Bonne NX, Baroncini M, Schapira S, Vincent C et al (2015) Causes of mortality in neurofibromatosis type 2. Br J Neurosurg 29(1):37\u201340","journal-title":"Br J Neurosurg"},{"issue":"4","key":"5020_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A et al (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358\u2013367","journal-title":"N Engl J Med"},{"issue":"35","key":"5020_CR5","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T et al (2019) Multicenter, prospective, phase II and biomarker study of High-Dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular Schwannoma. J Clin Oncol 37(35):3446\u20133454","journal-title":"J Clin Oncol"},{"issue":"8","key":"5020_CR6","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/neuonc\/noad066","volume":"25","author":"SR Plotkin","year":"2023","unstructured":"Plotkin SR, Allen J, Dhall G, Campian JL, Clapp DW, Fisher MJ et al (2023) Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related Schwannomatosis and progressive vestibular Schwannoma. Neuro Oncol 25(8):1498\u20131506","journal-title":"Neuro Oncol"},{"issue":"3","key":"5020_CR7","doi-asserted-by":"publisher","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"FP Nunes","year":"2013","unstructured":"Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A et al (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8(3):e59941","journal-title":"PLoS ONE"},{"issue":"11","key":"5020_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3109\/00207454.2015.1092443","volume":"126","author":"MC Alanin","year":"2016","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L et al (2016) Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2 - a retrospective case series. Int J Neurosci 126(11):1002\u20131006","journal-title":"Int J Neurosci"},{"issue":"4","key":"5020_CR9","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/annonc\/mdr012","volume":"22","author":"S Goutagny","year":"2011","unstructured":"Goutagny S, Raymond E, Sterkers O, Colombani JM, Kalamarides M (2011) Radiographic regression of cranial meningioma in a NF2 patient treated by bevacizumab. Ann Oncol 22(4):990\u2013991","journal-title":"Ann Oncol"},{"issue":"4","key":"5020_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5414\/NP301464","volume":"41","author":"E Basenach","year":"2022","unstructured":"Basenach E, F\u00f6rster A, Raab P, Alzein S, Schmidt G, Krauss JK et al (2022) Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the NF2:c.784C\u2009>\u2009T p.(Arg262*) variant. Clin Neuropathol 41(4):162\u2013167","journal-title":"Clin Neuropathol"},{"issue":"21","key":"5020_CR11","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1212\/WNL.0000000000000997","volume":"83","author":"J Blakeley","year":"2014","unstructured":"Blakeley J, Schreck KC, Evans DG, Korf BR, Zagzag D, Karajannis MA et al (2014) Clinical response to bevacizumab in schwannomatosis. Neurology 83(21):1986\u20131987","journal-title":"Neurology"},{"issue":"3","key":"5020_CR12","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1148\/radiol.2503080700","volume":"250","author":"W Cai","year":"2009","unstructured":"Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF et al (2009) Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 250(3):665\u2013673","journal-title":"Radiology"},{"issue":"21 Suppl 1","key":"5020_CR13","first-page":"S33","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG et al (2013) Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81(21 Suppl 1):S33\u201340","journal-title":"Neurology"},{"issue":"8","key":"5020_CR14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1093\/neuonc\/nos129","volume":"14","author":"S Goutagny","year":"2012","unstructured":"Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O et al (2012) Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 14(8):1090\u20131096","journal-title":"Neuro Oncol"},{"issue":"1","key":"5020_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","volume":"117","author":"MS Dirks","year":"2012","unstructured":"Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP et al (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg 117(1):109\u2013117","journal-title":"J Neurosurg"},{"key":"5020_CR16","doi-asserted-by":"publisher","first-page":"104408","DOI":"10.1016\/j.yexmp.2020.104408","volume":"114","author":"R Tamura","year":"2020","unstructured":"Tamura R, Sato M, Morimoto Y, Ohara K, Kosugi K, Oishi Y et al (2020) Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors. Exp Mol Pathol 114:104408","journal-title":"Exp Mol Pathol"},{"issue":"24","key":"5020_CR17","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","volume":"390","author":"SR Plotkin","year":"2024","unstructured":"Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL et al (2024) Brigatinib in NF2-Related schwannomatosis with progressive tumors. N Engl J Med 390(24):2284\u20132294","journal-title":"N Engl J Med"},{"issue":"6","key":"5020_CR18","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ et al (2012) Bevacizumab for progressive vestibular Schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33(6):1046\u20131052","journal-title":"Otol Neurotol"},{"issue":"12","key":"5020_CR19","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","volume":"272","author":"MC Alanin","year":"2015","unstructured":"Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L et al (2015) The effect of bevacizumab on vestibular Schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Otorhinolaryngol 272(12):3627\u20133633","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"5020_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart A, Gaillard V, Baroncini M, Andr\u00e9 N, Vannier JP, Vinchon M et al (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124(2):229\u2013236","journal-title":"J Neurooncol"},{"issue":"4","key":"5020_CR21","first-page":"281","volume":"3","author":"KA Morris","year":"2016","unstructured":"Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE et al (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract 3(4):281\u2013289","journal-title":"Neurooncol Pract"},{"issue":"14","key":"5020_CR22","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A et al (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-Associated vestibular schwannomas. J Clin Oncol 34(14):1669\u20131675","journal-title":"J Clin Oncol"},{"issue":"3","key":"5020_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0194599818809085","volume":"160","author":"P Sverak","year":"2019","unstructured":"Sverak P, Adams ME, Haines SJ, Levine SC, Nascene D, Sommer K et al (2019) Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on Patient-Reported outcomes and toxicities. Otolaryngol Head Neck Surg 160(3):526\u2013532","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"5020_CR24","doi-asserted-by":"publisher","first-page":"e28228","DOI":"10.1002\/pbc.28228","volume":"67","author":"S Renzi","year":"2020","unstructured":"Renzi S, Michaeli O, Salvador H, Alderete D, Ponce NF, Zapotocky M et al (2020) Bevacizumab for NF2-associated vestibular schwannomas of childhood and adolescence. Pediatr Blood Cancer 67(5):e28228","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-025-05020-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-025-05020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T06:47:31Z","timestamp":1750056451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-025-05020-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["5020"],"URL":"https:\/\/doi.org\/10.1007\/s11060-025-05020-1","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VN, IL, AM, OR, JCA, JOB, JLC, DWC, GD, RKJ, MAK, RJP, JT, NJU, BRK, and MJF declare no relevant competing interests. SRP is co-founder of NFlection Therapeutics and NF2 Therapeutics, and a consultant for Akouos and SonALAsense.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}